American Society of Hirudotherapy

[Research progress in hirudin fusion protein--review]

Review article published in Zhongguo shi yan xue ye xue za zhi (2007)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Salivary PharmacologyGenomics & ProteomicsZhang C et al. · Zhongguo shi yan xue ye xue za zhi, 2007

Abstract

Natural hirudin extracted from the secretion of medical leech salivary gland is a single-chain peptide containing 65 aminoacid residues with molecular weight of 7000 D, and exists in three isomers of HV1, HV2 and HV3. Hirudin possesses three disulfide bridges forming the structure of core cyclic peptides, which binds to the catalytic site of thrombin so as to inhibit the catalysis of thrombin. Its c-terminus rich in acidic aminoacid residues possesses hydrophilicity, and is free on the molecular surface, and can bind with fibrin recognition site of hirudin. The minimal segment of 12 - 16 C-terminal acidic residues keeps the minimal activity of anti-thrombosis. Thus, hirudin, as a potent and specific inhibitor of thrombin, can be used to protect from and to treat clinically thrombosis. As it has some disadvantages such as short half-life, bleeding side-effect and mono-function, and so on, hirudin has been fused with some other functional proteins in recent years. The obtained fusion proteins can prolong the half life of hirudin, or relieve it bleeding side effect, or bring new functions, such as thrombolysis, inhibiting the platelet aggregation, targeting specifically. The research progress in hirudin fusion protein was summarized in this review.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal ArticleReview
Indexed MeSH termsAnticoagulantsDelayed-Action PreparationsDrug Delivery SystemsGlucokinaseHirudinsHumansPlatelet Aggregation InhibitorsRecombinant Fusion ProteinsUrokinase-Type Plasminogen Activator

Summary

Natural hirudin extracted from the secretion of medical leech salivary gland is a single-chain peptide containing 65 aminoacid residues with molecular weight of 7000 D, and exists in three isomers of HV1, HV2 and HV3.

Why This Matters for Hirudotherapy

Advances understanding of leech salivary bioactive compounds and their therapeutic potential.

Citation

[Research progress in hirudin fusion protein--review].

Zhang C et al. · Zhongguo shi yan xue ye xue za zhi, 2007

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

[Research progress in hirudin fusion protein--review] | ASH